By measuring BNP levels in asymptomatic patients with MS, hemodynamically significant lesions may be identified earlier on and potentially reduce the occurrence of adverse events such as heart failure and number or frequency of hospitalizations. The gene discussed is NPPB; the disease is myeloid sarcoma.